HRS4R
Vull donar

ROSA COLL JORDA

Firma
ROSA COLL-JORDA
Posició
Investigadors/es Col·laboradors/es
Investigadors/es Col·laboradors/es

Publicacions

0

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.

HemaSphere, 2023, 7 dx.doi.org/10.1097/HS9.0000000000000810

Oñate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol MA, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.

Blood Advances, 2022, 6, 882-890 dx.doi.org/10.1182/bloodadvances.2020004136

Bataller A, Garrido A, Guijarro F, Oñate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, Queipo DE Llano MP, Coll R, Gallardo D, Vall-Llovera F, Escoda L, García-Guiñon A, Salamero O, Sampol A, Merchan B, Bargay J, Castaño-Díez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, López-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.

Blood Advances, 2022, 6, 1193-1206 dx.doi.org/10.1182/bloodadvances.2021005585

Ribera J, Granada I, Morgades M, González T, Ciudad J, Such E, Calasanz MJ, Mercadal S, Coll R, González-Campos J, Tormo M, García-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermúdez A, Orfao A, Ribera JM

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.

BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196, 670-675 dx.doi.org/10.1111/bjh.17844
0

5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics

EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109, 755-764 dx.doi.org/10.1111/ejh.13862

Martinez-Verbo L, Estrada N, Cabezón M, Palomo L, García O, Arnan M, Coll R, Xicoy B, Zamora L

Mutational profile and relative telomere length in Chronic Myelomonocytic Leukemia subgroups according to the 2016 World Health Organization classification.

LEUKEMIA RESEARCH, 2021, 111, 106726-106726 dx.doi.org/10.1016/j.leukres.2021.106726

Ribera JM, Morgades M, Genescà E, Chapchap EC, Montesinos P, Acuña-Cruz E, Gil C, García-Cadenas I, Barba P, González-Campos J, Queipo de Llano MP, Torrent A, Ribera J, Granada I, Bernal T, Díaz-Beyá M, Amigo ML, Coll R, Tormo M, Vall-Llovera F, Gómez-Centurión I, Sánchez-Sánchez MJ, Soria B, Cladera A, Artola MT, Garcia-Guiñon A, Giménez-Conca A, Amador ML, Martínez-Sánchez P, Algarra JL, Vidal MJ, Alonso N, Maluquer C, Llorente L, García-Boyero R, Ciudad J, Feliu E, Orfao A, on behalf of the PETHEMA Group

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials.

HEMATOLOGICAL ONCOLOGY, 2021, 39, 529-538 dx.doi.org/10.1002/hon.2910

Genescà E, Morgades M, González-Gil C, Fuster-Tormo F, Haferlach C, Meggendorfer M, Montesinos P, Barba P, Gil C, Coll R, Moreno MJ, Martínez-Carballeira D, García-Cadenas I, Vives S, Ribera J, González-Campos J, Díaz-Beya M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermúdez A, Vall-Llovera F, Martínez-Sánchez P, Amigo ML, Monsalvo S, Novo A, Cervera M, García-Guiñon A, Ciudad J, Cervera J, Hernández-Rivas JM, Granada I, Haferlach T, Orfao A, Solé F, Ribera JM

Adverse prognostic impact of complex karyotype (=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).

LEUKEMIA RESEARCH, 2021, 109, 106612-106612 dx.doi.org/10.1016/j.leukres.2021.106612

Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesca E, Barba P, Ribera J, García Cadenas I, Moreno MJ, Martínez-Carballeira D, Torrent A, Martínez-Sánchez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, González-Campos J, Rodríguez-Medina C, Bermúdez A, Novo A, Soria B, Coll R, Amigo ML, López A, Fernández Martín R, Serrano J, Mercadal S, Cladera A, Giménez-Conca AD, Peñarrubia MJ, Abella E, Vall-Llovera F, Hernández-Rivas JM, Garcia A, Bergua Burgues JM, de Rueda B, Sánchez-Sánchez MJ, Serrano A, Calbacho M, Alonso Vence N, Méndez-Sánchez JÁ, García-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A

Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.

Blood, 2021, 137, 1879-1894 dx.doi.org/10.1182/blood.2020007311

Cabezón M, Malinverni R, Bargay J, Xicoy B, Marcé S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jiménez MJ, Hoyos M, Valcárcel D, Escoda L, Vall-Llovera F, Garcia A, Font LL, Rámila E, Buschbeck M, Zamora L, CETLAM group

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.

CLINICAL EPIGENETICS, 2021, 13, 9-9 dx.doi.org/10.1186/s13148-021-01002-y

Formulari de contacte

Coneix l’IDIBGI!

menu